logo
Share SHARE
FONT-SIZE Plus   Neg

Myriad Genetics Gets Rights To RAD51C Gene

Myriad Genetics, Inc. (MYGN: Quote) said Wednesday it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.

In several studies, mutations in the RAD51C gene have been identified and associated with an increased risk for hereditary breast and ovarian cancer.

RAD51C was identified initially as a susceptibility gene for hereditary breast and ovarian cancer by members of the German Consortium for Hereditary Breast and Ovarian cancers in collaboration with pediatric hematologists and basic scientists predominantly located at the universities of Cologne, Dusseldorf and Munich.

Through this agreement, Myriad has obtained an exclusive, world-wide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
JetBlue Airways is all set to begin direct flights to Cuba from New York beginning July 3. "The Rift delivers on the dream of consumer VR with compelling content, a full ecosystem, and a fully-integrated hardware/software tech stack," the Facebook-owned virtual reality technology firm said. Germanwings co-pilot Andreas Lubitz, who appears to have deliberately crashed the aircraft on French Alps, had rehearsed controlled descent on another flight that morning, investigators said. The crash has killed 150 people aboard the Germanwings Flight 9525 on March 24.
comments powered by Disqus
RELATED NEWS
Trade MYGN now with 
Follow RTT